Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Diabet Med 2009
1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87
The global GLP-1 targeted peptide weight loss drugs market size was calculated at USD 61.18 billion in 2024 and is expected to reach USD 193.44 billion by 2034, expanding at a CAGR of 12.2% between 2025 and 2034
Taking it twice a day is off-label, unsafe, and significantly raises the risk of severe insomnia, tachycardia, hypertension, and cardiac events
US$ 20.68
US$ 20.40
US$ 20.94
US$ 26.76
US$ 25.76
US$ 26.27
US$ 23.65
US$ 20.12
US$ 21.98
US$ 25.95
US$ 23.15
US$ 22.96
